RE: hey pepito, with 411 200 000 o/s Good question.
What do we need to see $ 1.00 par shares?
Giving the fact that at 14 cents, the market give no value to the therapeutic and the potential revenues of deals like wuhan, I will use more the pattern of a "revenues company" instead of tabling on the potential of the therapeutic.
According to the link below, the sector is showing a 20 times P/E average, but small biotech are unlikely trading on a 10 to 15 time the P/E.
Let's use the more conservative 10 times P/E, as the market confidence is not reaaly strong at the moment.
Base on this, PLI would need a $ 41M net income. Using a gross margin of 65% on the sales of resins (per the financials statement info), and considering a $ 17M of administrative, R&D and interest expenses, PLI would need in these conditions $ 80M in revenues.
Any significant deal with upfront, or large future potential for income, or any partnership or join venture that would make the market believing in the potential of Newco or the therapeutic could push the P/E to 20 times or $ 40M.
I believe when the potential of the future revenues from such as Wuhan, Octapharma, the unknow global pharma that made orders in 2009 and 2011 for their phase III trial, the PPPS deals and Newco, and the real value of the therapeutictial of the therapeutic, I think I can see $ 1.00 with $ 40M a year, as long as the indicators will keep showing revenues growth.
Afterall, I have seen a lot of one trick poney on the NASDAQ having much bigger market cap than PLI, with less to offer.
Wishfull thinking, maybe, but we never know!
https://biz.yahoo.com/p/515conameu.html